Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pertuzumab plus trastuzumab in metastatic breast cancer.
Şendur MA, Aksoy S, Zengin N. Şendur MA, et al. N Engl J Med. 2012 Apr 5;366(14):1348; author reply 1349-50. doi: 10.1056/NEJMc1201462. N Engl J Med. 2012. PMID: 22475602 No abstract available.
Pertuzumab in HER2-positive breast cancer.
Sendur MA, Aksoy S, Altundag K. Sendur MA, et al. Curr Med Res Opin. 2012 Oct;28(10):1709-16. doi: 10.1185/03007995.2012.728132. Epub 2012 Oct 11. Curr Med Res Opin. 2012. PMID: 22953713 Review.
Everolimus: a new hope for patients with breast cancer.
Sendur MA, Zengin N, Aksoy S, Altundag K. Sendur MA, et al. Curr Med Res Opin. 2014 Jan;30(1):75-87. doi: 10.1185/03007995.2013.846253. Epub 2013 Oct 14. Curr Med Res Opin. 2014. PMID: 24050600 Review.
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K. Boyraz B, et al. Among authors: sendur ma. Curr Med Res Opin. 2013 Apr;29(4):405-14. doi: 10.1185/03007995.2013.775113. Epub 2013 Mar 1. Curr Med Res Opin. 2013. PMID: 23402224 Review.
172 results